Click Here For COVID-19 (Coronavirus) Studies

RecruitMe Clinical Trial

A Phase 1/2 Study of REGN4018 Administered Alone or in Combination with Cemiplimab in Patients with Platinum-Resistant Ovarian Cancer
Study of REGN4018 Alone or in Combination with Cemiplimab in Patients with Ovarian Cancer
Sponsor:Regeneron Pharmaceuticals, Inc.
Enrolling:Female Patients Only
Minimum Age:18 years old
IRB Number:AAAR8226
U.S. Government ID:NCT03564340
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

The main purpose of this study is to: Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer.

Do You Qualify?
Are you a woman who is 18 years of age or older?YesNo
Do you have ovarian cancer?YesNo
Are you willing and able to comply with clinic visits and study-related procedures, including undergoing study biopsies?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162